1 ) and the British Committee for Standards in Haematology (2003), issues surrounding the diagnosis and

2 idered the effect of adjusting for 15 common haematology and biochemistry test results or proxies for

3                                   15 routine haematology and biochemistry test results were highly pr

4 nt defined clinically or by changes in blood haematology and biochemistry variables, measured monthly

5 titute of Pathology/Department of Paediatric Haematology and Oncology, Hannover Medical School) from

6  tested for viraemia, undertook analyses for haematology and serum biochemistry, and measured humoral

7 laboratory analytes (ie, serum chemistry and haematology), and participant incidence of denosumab ant

8 lected blood samples for clinical chemistry, haematology, and filovirus antibodies using ELISA.

9 e German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric

10 (ASH) and British Committee for Standards in Haematology (BCSH) guidelines indicate that at platelet

11                                              Haematology, biochemistry, and CD4-cell counts were done

12 dence of advanced disease including abnormal haematology, blood chemistry and coagulopathy, siRNA-tre

13 ry variables, including lipid panel, routine haematology, blood chemistry, urinalysis, coagulation, a

14 -containing salvage therapy from 12 oncology-haematology centres in Italy.

15 e cell anaemia in steady state attending the Haematology clinic of a federal tertiary health institut

16 ractice guidelines by the British Paediatric Haematology Group in 1992 and by the American Society of

17 ology and British Committee for Standards in Haematology guidelines for the diagnosis and management

18 d the effect of treatment on body condition, haematology, immune function, physiological stress and o

19 ranging from 37% in renal/transplant, 29% in haematology/oncology, and 28% in acute/elderly medicine

20 t feeding, clinical status, and biochemistry/haematology results were collected in a separate infant

21 from use of adult haemopoietic stem cells in haematology will facilitate and hasten transition from l